manganese-52 BPPA-bevacizumab

manganese-52 BPPA-bevacizumab is an experimental **VEGF-A-targeted immuno-PET radiopharmaceutical** consisting of the anti-VEGF monoclonal antibody bevacizumab conjugated to the BPPA chelator and labeled with the positron-emitting isotope manganese-52. The agent is designed for **PET or PET/MRI visualization of VEGF-A expression** in tumors rather than for direct therapy, using bevacizumab to bind soluble vascular endothelial growth factor A and manganese-52 to generate imaging signal over the prolonged time window needed for full-length antibody pharmacokinetics. In the provided preclinical work, it was evaluated in KB-3-1 cervical carcinoma xenografts and showed sustained tumor uptake with improved tumor-to-background ratios versus the earlier manganese-52 DOTAGA-bevacizumab construct, supporting its development as a next-generation biologic imaging tracer for angiogenesis-driven malignancies and for potential selection or monitoring of patients receiving anti-angiogenic therapy.

Other names

BPPA-bevacizumabmanganese-52 BPPA bevacizumabmanganese52 BPPA bevacizumabmanganese 52 BPPA bevacizumab